摘要
目的探讨厄洛替尼辅助全脑放疗治疗非小细胞肺癌脑转移患者的临床疗效。方法选取2010年1月～2014年12月间来我院治疗的非小细胞肺癌脑转移患者28例作为观察组。所有患者均经病理或细胞学确诊为非小细胞肺癌，给予常规内科对症和支持治疗，如缓解颅内水肿等。在此基础上进行全脑放疗治疗（DT=30GY，每次3GY，分10次）以及厄洛替尼辅助治疗。观察2个月后患者的临床治疗效果。选取同期只接受放疗患者30例为对照组。结果治疗2个月后，观察组完全缓解0例，部分缓解17例，稳定11例，进展0例，临床获益率为100．00％，临床有效率为60．71％。对照组完全缓解0例，部分缓解9例，稳定15例，进展6例，临床获益率为80．00％，临床有效率为33．33％。观察组临床获益率与临床有效率明显高于对照组（P〈0．05）。观察组皮疹12例（42．8％），腹泻7例（25．0％），乏力24例（85．7％），脱发6例（21．4％），粒细胞降低2例（7．1％）。对照组皮疹11例（36．7％），腹泻7例（23．3％），乏力25例（83．3％），脱发7例（23．3％），粒细胞降低4例（13．3％）。两组不良反应比较差异无统计学意义（P〉0．05）。结论厄洛替尼辅助全脑放疗治疗非小细胞肺癌脑转移患者具有较好的临床疗效，值得推广应用。
Objective To explore the clinical efficacy of erlotinib assisted whole brain radiotherapy in the treatment of patients with brain metastasis of non-small cell lung cancer. Methods A total of 28 patients with brain metastasis of non-small cell lung Cancer treated in our hospital from January 2010 to December 2014 were selected as the observa- tion group. All the patients were diagnosed with non-small cell lung cancer by pathology or cytology and given conven- tional internal medicine symptomatic and supportive treatment, such as remission of intraeranial edema, on the basis of which whole brain radiotherapy （DT=30 GY, 3 GY/time, 10 times） and erlotinib adjuvant therapy were conducted. The patients＇ clinical treatment effects were observed 2 months later. Thirty patients only receiving radiotherapy in the cor- responding period were selected as the control group. Results after 2 months of treatment, In the observation group, none remitted completely, 17 patients remitted partially, 11 patients stabilized and none progressed, with the clinical benefit rate of 100.00% and the clinical effective rate of 60.71%. In the control group, none remitted completely, 9 pa- tients remitted partially, 15 patients stabilized and 6 patients progressed, with the clinical benefit rate of 80.00% and the clinical effective rate of 33.33%. The observation group was significantly higher than the control group in the clinical benefit rate and the clinical effective rate （P〈0.05）. In the observation group, there were 12 patients （42.8%） with rash, 7 patients（25.0%） with diarrhea, 24 patients（85.7%） with fatigue, 6 patients（21.4%） with alopecia and 2 patients（7.1%） with decreased granulocyte. In the control group, there were 11 patients （36.7%） with rash, 7 patients （23.3%） with diar- rhea, 25 patients（83.3%） with fatigue, 7 patients （23.3%） with alopeeia and 4 patients （13.3%） with decreased granuloeyte. The two groups were not significantly different in the adverse reactions （P〉0.05
出处
《中国现代医生》
2015年第28期37-40,共4页
China Modern Doctor
基金
江西省新余市科技计划项目(20123090809)
关键词
厄洛替尼
非小细胞肺癌
放疗
脑转移
Erlotinib
Non-small cell lung cancer
Radiotherapy
Brain metastases
